Prognosis
GSK Says Antibody Works on Omicron Mutations in Early Tests
- Lab experiments suggest treatment holds up against new variant
- Antibody wins clearance from U.K.’s medicines regulator
This article is for subscribers only.
GlaxoSmithKline Plc said its Covid-19 antibody treatment looks to be effective against the new omicron variant in early tests.
Lab tests of the mutations found in the variant showed the drug is still active against the virus, Glaxo said in a statement Thursday. The drugmaker is now conducting in vitro experiments to confirm the response against a combination of all the omicron mutations.